Browsing by Author "Indrajeet S. Gambhir"

Now showing 1 - 5 of 5

Cerebrospinal Fluid Protein Profiles in Alzheimer's Dementia Patients: A Bioinformatic Approach
(Wolters Kluwer Medknow Publications, 2023) Anamika Misra; Sankha S. Chakrabarti; Indrajeet S. Gambhir; Meghraj S. Baghel; Yugendra R. Patil
[No abstract available]
Delayed neuroleptic malignant syndrome associated with the use of low dose risperidone in conjunction with cholinergic drugsthe dangers of polypharmacy in the elderly
(Bentham Science Publishers B.V., 2018) Upinder Kaur; Sankha S. Chakrabarti; Indrajeet S. Gambhir; Deepak K. Gautam
Background: Neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction with systemic manifestations like fever, rigidity, altered sensorium and autonomic disturbances. The syndrome is often seen within days to weeks in patients being treated with antipsychotics. Though reported with the use of atypical antipsychotics, it is relatively uncommon to occur if patient is on a stable dose of antipsychotic for a long time. Objective: Here we report a case of delayed NMS with risperidone use at the lowest recommended dose. Method: Review of probable etiology including drug review was performed in a 60 year hypertensive female presenting with progressive limitation of movements and rigidity in upper and lower limbs along with bilateral hand tremors, fever, poor speech, difficulty in swallowing, agitated behavior, urinary incontinence and altered mental status. Results: NMS occurred in the patient of schizophrenia on the lowest possible therapeutic dose of risperidone of 0.5 mg/day, after 14 years of therapy. The case highlights the possible drug interaction between risperidone and cholinergic drugs resulting in the catastrophe. (Videos before and after therapy are part of submission) Conclusion: Physicians should be vigilant of the risk of NMS with atypical antipsychotics like risperidone particularly when administered along with cholinergic drugs. NMS can occur even after long term use of a stable dose of antipsychotic. Cholinergic drugs like donepezil, citicoline and piracetam should be used with caution in patients who are already on antipsychotics and if needed should be added one by one. © 2018 Bentham Science Publishers.
Iron Isomaltoside-Induced Anaphylaxis
(Lippincott Williams and Wilkins, 2022) Upinder Kaur; Amit Singh; Indrajeet S. Gambhir; Shubham Kashyap; Anup Singh; Sankha S. Chakrabarti
[No abstract available]
Isoniazid induced metabolic acidosis and renal dysfunction in an elderly patient with chronic renal disease
(Bentham Science Publishers B.V., 2016) Upinder Kaur; Sankha S. Chakrabarti; Indrajeet S. Gambhir
Metabolic acidosis is one of the common manifestations of Isoniazid toxicity but rare with normally used doses of the drug. Among anti tubercular drugs, rifampicin, streptomycin and capreomycin are commonly implicated in renal injury. Here we report the first case of metabolic acidosis and renal injury caused by isoniazid at normal prescribed dose. © 2016 Bentham Science Publishers.
Newer insights in personalized and evidence based medicine- The role of microRNAs
(Bentham Science Publishers B.V., 2016) Upinder Kaur; Sankha S. Chakrabarti; Indrajeet S. Gambhir
Background: MicroRNAs are non-coding RNAs which regulate gene expression by binding to 3’ UTR site on mRNA. These small RNAs repress gene expression by interfering with the process of translation or by degrading the target mRNA. Abnormal expression of miRNAs has been implicated in a wide spectrum of human diseases like atherosclerosis, cancers and diabetes. Traditionally, pharmacogenomics focuses on single nucleotide polymorphisms and copy number variants of genes implicated in pharmacokinetics and pharmacodynamics. Recently, drug response has been proposed to be regulated by microRNAs. Mutations involving miRNAs can contribute to disease pathogenesis and modulation of drug response. Objective: The main objective of this review is to highlight the role of miRNAs in biological processes leading to disease states as well as in the field of drug action and pharmacogenomics. Method: A literature review was performed incorporating the latest insights in the field of miRNA therapeutics, diagnostics and pharmacogenomics. Results: Altered expression of miRNAs is seen in diabetes, vascular inflammation, atherosclerosis, infection and cancers. In the field of miRNA- pharmacogenomics, maximum work has been done studying the resistance to anticancer drugs. Some examples of microRNAs regulating drug response are miR-24 influencing the response to methotrexate, miR-125b affecting the action of calcitriol and miR-27b regulating the expression of CYP3A4. Among miRNAs currently being targeted in therapeutics are miR-122, miR- 33, miR-21, let-7 and miR-34. Conclusion: A significant fraction of all mRNAs transcribed in a cell are regulated by miRNAs. miRNAs implicated in a given disease may interfere with drug action and metabolism. Further research is needed to understand the association between miRNA, mRNAs, diseases and pharmacokinetics and dynamics. © 2017 Bentham Science Publishers.